Research / Clinical Trials
Our practice offers clinical trials which help determine whether newly developed treatments are safe and effective in treating Multiple Sclerosis. These studies are important research tools for the developing new treatment options for this chronic disease. Clinical trials also provide patients with access to new treatment options and new therapies that are not offered to the general population.
As new technologies and therapeutic options become available, Hope Neurology Multiple Sclerosis Center utilizes clinical trials to provide innovative treatment options to our patients.
Clinical research studies provide patients with new medications and access to comprehensive disease management. By working closely with our pharmaceutical sponsors, we strive to improve the health, hope and well-being of our patients.
For more information on any of our studies, please call 865. 218.6222 and ask to speak with Brenda, Geneva or Linsey or email us at email@example.com
—–Enrolling Clinical Trials:
Exchange Study: Clinical Trial Protocol Number CBAF312AUS02
Exploring the safety and tolerability of conversion from oral or injectable disease modifying therapies to dose-titrated Oral Siponimod in patients with advancing forms of relapsing remitting multiple sclerosis: A 6 month open label, multi-center Phase IIIb study.
Enlighten Study: Clinical Trial Protocol Number RPC-1063-MS-001
This is a multicenter, longitudinal, single-arm, open-label study to describe the change from baseline in cognitive processing speed, measured by the SDMT, in subjects with RMS treated with ozanimod HCl 1 mg at 3 years.
Ongoing Clinical Trials
Ultimate: Clinical Trial Protocol TG1101-RMS-303
TG1101-RMS303 is an open-label, single-arm extension study designed to evaluate long-term safety and efficacy of ublituximab in subjects with Relapsing Multiple Sclerosis. Subjects who complete the 96-week, double-blind treatment period of TG1101-RMS301 or TG1101-RMS302 are eligible for participation in this Open Label Extension (OLE) study.